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Abstract
Backgrounds and Aims: The presence and progression of vascular calcification have been demonstrated as important risk
factors for mortality in dialysis patients. However, since the majority of subjects included in most previous studies were
hemodialysis patients, limited information was available in peritoneal dialysis (PD) patients. Therefore, the aim of this study
was to investigate the prevalence of aortic arch calcification (AoAC) and prognostic value of AoAC progression in PD
patients.
Methods: We prospectively determined AoAC by chest X-ray at PD start and after 12 months, and evaluated the impact of
AoAC progression on mortality in 415 incident PD patients.
Results: Of 415 patients, 169 patients (40.7%) had AoAC at baseline with a mean of 18.1611.2%. The presence of baseline
AoAC was an independent predictor of all-cause [Hazard ratio (HR): 2.181, 95% confidence interval (CI): 1.336–3.561,
P= 0.002] and cardiovascular mortality (HR: 3.582, 95% CI: 1.577–8.132, P= 0.002). Among 363 patients with follow-up chest
X-rays at 12 months after PD start, the proportion of patients with AoAC progression was significantly higher in patients
with baseline AoAC (64.2 vs. 5.3%, P,0.001). Moreover, all-cause and cardiovascular death rates were significantly higher in
the progression groups than in the non-progression group (P,0.001). Multivariate Cox analysis revealed that AoAC
progression was an independent predictor for all-cause (HR: 2.625, 95% CI: 1.150–5.991, P= 0.022) and cardiovascular
mortality (HR: 4.008, 95% CI: 1.079–14.890, P= 0.038) in patients with AoAC at baseline.
Conclusions: The presence and progression of AoAC assessed by chest X-ray were independently associated with
unfavorable outcomes in incident PD patients. Regular follow-up by chest X-ray could be a simple and useful method to
stratify mortality risk in these patients.
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Introduction
Cardiovascular disease is the most common cause of morbidity
and mortality in patients with end-stage renal disease (ESRD) [1].
Since traditional risk factors, such as advanced age, hypertension,
diabetes, smoking, and dyslipidemia, cannot fully account for the
high prevalence of cardiovascular disease, uremia-related factors,
including inflammation and oxidative stress, have been implicated
in the pathogenesis of cardiovascular disease in ESRD patients [2].
Recently, accumulating evidence has shown that disturbances in
calcium-phosphorus metabolism also play a pivotal role in
cardiovascular disease, partly via the development of vascular
calcification [2,3,4].
Vascular calcification is not uncommon in general elderly
population; 20–30% of people older than 65 years have
calcification in the aorta [5]. In patients with chronic kidney
disease (CKD), this proportion is reported to be substantially
higher; more than one half of CKD patients even before the start
of dialysis and up to 80–90% of ESRD patients have some form of
vascular calcification [6,7]. Previous studies have revealed vascular
calcification is independently associated with all-cause and
cardiovascular mortality in both general population and ESRD
[3,8,9,10,11]. Moreover, since vascular calcification progresses
rapidly in dialysis patients, ESRD patients with the progression of
vascular calcification are demonstrated to have an unfavorable
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outcome [12]. Therefore, not only the identification of vascular
calcification but also risk stratification of patients by the changes in
vascular calcification may be important for clinicians to manage
dialysis patients.
To date, a number of techniques are available to detect vascular
calcification. Electron beam computed tomography (EBCT),
multi-slice CT (MSCT), planar X-ray (such as plain X-ray of
lateral abdomen, pelvis, and hands), 2D ultrasonography, and
echocardiography have been used to assess vascular calcification
[6,9,10,13,14,15,16,17]. Among these, EBCT and MSCT are
well-validated noninvasive imaging methods that are considered
the golden standard for quantifying vascular calcification. How-
ever, EBCT and MSCT cannot be routinely performed due to the
relatively high cost of testing and exposure to a high radiation dose
[16]. Recently, aortic arch calcification (AoAC) in plain chest X-
rays was found to reflect the magnitude of whole aortic
calcification in general population and dialysis patients [15,16].
In addition, several previous studies showed that AoAC was an
independent predictor of cardiovascular events and that AoAC
progression was significantly associated with increased cardiovas-
cular mortality in patients with ESRD [3,11,18,19]. However,
since the majority of subjects included in most previous studies
were ESRD patients on hemodialysis (HD), little is known about
the prevalence, natural history, and prognostic value of vascular
calcification in peritoneal dialysis (PD) patients. In the present
study, we investigated the prevalence of AoAC at PD initiation
and the frequencies of AoAC progression or regression during the
first year after PD. The impact of AoAC progression on all-cause
and cardiovascular mortality was also determined.
Methods
Ethics Statement
The study was carried out in accordance with the Declaration of
Helsinki and approved by the Institutional Review Board of
Yonsei University Health System Clinical Trial Center. We
obtained informed written consent from all participants involved
in our study.
Patients
All consecutive ESRD patients over 18 years of age who started
PD at Yonsei University Health System between January 2005
and June 2010 were initially included in this prospective
observational study. Among a total of 530 incident PD patients,
patients with PD duration of less than 3 months, active infection,
malignancy, and decompensated liver cirrhosis were excluded.
Thus, the remaining 415 patients were included in the final
analysis.
Demographic and Clinical Data Collection
A well-trained examiner used a questionnaire at the time of PD
start to collect demographic data. Traditional cardiovascular risk
factors such as age, hypertension, diabetes mellitus, smoking
history, and previous history of cardiovascular disease were
recorded. In smokers, the amount of smoking was expressed as
pack-years; the product of the number of cigarette packs
consumed per day by the duration of smoking (years). Cardiovas-
cular disease was defined as a history of coronary, cerebrovascular,
or peripheral vascular disease: coronary disease was defined as a
history of angioplasty, coronary artery bypass grafts, myocardial
infarction, or angina and cerebrovascular disease as a history of
transient ischemic attack, stroke, or carotid endarterectomy, while
peripheral vascular disease was defined as a history of claudication,
ischemic limb loss and/or ulceration, or peripheral revasculariza-
tion procedure. Patients were weighed in light clothing and height
was measured with no shoes. Body mass index (BMI) was
calculated as weight/height2 (kg/m2). Blood was drawn after a
12-hour overnight fasting, and the following laboratory data were
measured from blood samples: hemoglobin, blood urea nitrogen,
creatinine, calcium, phosphorus, albumin, total cholesterol,
triglyceride, low density lipoprotein (LDL)-cholesterol, high
density lipoprotein (HDL)-cholesterol, and intact parathyroid
hormone (iPTH) concentrations. In addition, high sensitivity C-
reactive protein (hs-CRP) levels were determined by a latex-
enhanced immunoephelometric method using a BN II analyzer
(Dade Behring, Newark, DE, USA). To reflect the actual situation,
usual overnight dialysate volume and glucose concentrations were
not changed for this study. Kt/V urea was determined from the
total loss of urea nitrogen in spent dialysate using PD Adequest 2.0
for Windows software (Baxter Healthcare, Deerfield, Illinois,
USA). The modified peritoneal equilibration test was performed
with 4.25% glucose dialysis solution as described previously [20]
and the dialysate-to-plasma creatinine (D/P Cr) and glucose (D/
D0 glucose) concentration ratios at 4 hours of dwell were used to
describe the peritoneal transport characteristics; high, high
average, low average, and low.
Assessment of AoAC by Chest X-ray
To determine AoAC extent, two trained medical doctors
blinded to the patients’ clinical data reviewed posterior-anterior
plain chest X-rays taken at the start of PD using a specific scale
developed by Ogawa et al [16]. This scale, which divides the
aortic arch into 16 sections by circumference, was attached to the
aortic arch on chest X-rays and the number of sectors was divided
by 16. AoAC scores (AoACS) were calculated after multiplication
by 100 to express results as a percentage. To confirm the intra-
reader variability, randomly selected 100 chest X-rays were
reexamined by the same reader. The median intra-class correla-
tion coefficient for AoACS was 0.91 [95% confidence interval (CI):
0.71 to 0.99] and 0.90 (95% CI: 0.69 to 0.98) in two readers. In
addition, any discrepancies between the two observers were
resolved by an independent third reader. Progression of AoAC was
defined as an increase in AoACS on the follow-up chest X-ray
taken 1 year after PD initiation.
Follow-up and Endpoints
All patients included in this study were regularly followed-up at
the PD clinic, and all deaths and hospitalization were recorded in
the serious adverse events database. Mortality events were
retrieved from the database and carefully reviewed to determine
all-cause and cardiovascular mortality. Cardiovascular mortality
was considered death from myocardial infarction or ischemia,
congestive heart failure, pulmonary edema, and cerebral hemor-
rhage or vascular disorder.
Among 415 patients, follow-up chest X-rays at 12 months were
not available in 52 patients; 30 died within 12 months of PD start,
11 changed dialysis modality to HD, 9 underwent kidney
transplantation, and 2 were transferred to other PD units.
Therefore, the association between the progression of AoAC and
survival was analyzed in 363 patients.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows
version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous
variables were expressed as mean 6 SD, and categorical
variables were expressed as a number (percentage). Since hs-
CRP did not yield a Gaussian distribution, log values were
used. In the first analysis, 415 patients were divided into two
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groups according to the presence of AoAC at baseline. To
determine differences between the two groups, a Student’s t-test
and the chi-square test were performed for continuous variables
and categorical variables, respectively. Multivariate binary
logistic regression models were used to identify significant
determinants of AoAC presence at PD initiation. Cumulative
survival curves were generated by the Kaplan-Meier method,
and between-group survival was compared by a log-rank test.
Independent prognostic values of AoAC at baseline for all-cause
and cardiovascular mortality were ascertained by Cox propor-
tional hazards models, which included only the significant
variables in univariate analysis. Meanwhile, the progression of
AoAC was focused in the second analysis. In the second
analysis, mean values of the biochemical parameters during the
first year of PD were used. Pearson’s correlation analysis was
performed to estimate association between the changes in
AoACS and other continuous variables. Multivariate binary
logistic regression models, which included significant variables in
univariate analysis, were constructed to determine significant
independent predictors of AoAC progression. Subgroup analysis
was also performed according to the presence of baseline
AoAC. The impact of AoAC progression on patient outcome
was examined by the Kaplan-Meier method and Cox propor-
tional hazards regression analysis. Significant variables in
univariate analysis, traditional risk factors (age, sex, and diabetes
mellitus), and factors associated with inflammation and nutrition
(serum hs-CRP and albumin concentrations) were included in
multivariate Cox proportional hazard models. A P value less
than 0.05 was considered statistically significant.
Results
Clinical Characteristics According to the Presence of
AoAC at Baseline
Baseline patient characteristics according to the presence of
AoAC at baseline are shown in Table 1. The mean age was
55.8613.8 years (21–80 years), and 234 patients (56.3%) were
male. Of 415 patients, 169 patients (40.7%) had AoAC at
baseline with a mean AoACS of 18.1611.2%. Diabetic
nephropathy was the most common cause of ESRD, followed
by chronic glomerulonephritis in both groups. The mean age,
the proportion of patients with diabetes and previous history of
cardiovascular disease, and the proportion of patients taking
lipid-lowering agents and b-blockers were significantly higher in
patients with AoAC at baseline. In addition, compared to
patients without baseline AoAC, total cholesterol, iPTH, and
albumin concentrations were significantly lower, while hs-CRP
levels were significantly higher in the baseline AoAC present
group. Moreover, even though the proportion of smoker was
significantly lower, the mean amount of smoking was signifi-
cantly greater in patients with baseline AoAC. Among 224
patients (53.9%), who performed echocardiography at baseline,
the ejection fraction was significantly lower in patients with
baseline AoAC compared to the baseline AoAC absent group.
On the other hand, there were no significant differences in
peritoneal membrane transport characteristics, weekly Kt/V
urea, systolic blood pressure, BMI, calcium-phosphate (Ca x P)
product values, and the use of phosphate binders between the
two groups.
Association of Various Parameters with the Presence of
AoAC at Baseline
In univariate analysis, age, diabetes mellitus, previous history of
cardiovascular disease, smoking, lipid-lowering therapy, serum
albumin, iPTH, and hs-CRP concentrations were significantly
associated with the presence of AoAC at baseline. Multivariate
binary logistic regression analysis revealed that age [odds ratio
(OR): 1.101, 95% CI: 1.066–1.138, P,0.001] and previous
history of cardiovascular disease (OR: 2.084, 95% CI: 1.006–
4.314, P=0.048) were significant independent factors associated
with the presence of AoAC at baseline.
Table 1. Baseline characteristics of the patients with and
without aortic arch calcification (AoAC).
Characteristics With AoAC Without AoAC P
Number (%) 169 (40.7%) 246 (59.3%)
Age (years) 66.769.3 52.1613.1 ,0.001
Male, n (%) 88 (52.0%) 146 (59.3%) NS
Diabetes mellitus, n (%) 104 (61.5%) 92 (37.3%) ,0.001
Primary renal disease, n (%) NS
Glomerulonephritis 38 (22.4%) 73 (29.6%)
Diabetes mellitus 86 (50.9%) 84 (34.1%)
Hypertensive nephrosclerosis 12 (7.1%) 21 (8.5%)
Polycystic kidney disease 1 (0.6%) 4 (1.6%)
Others/Unknown 32 (18.9%) 64 (26.0%)
Peritoneal equilibration test, n
(%)
NS
High 7 (4.1%) 24 (9.8%)
High average 123 (72.7%) 126 (51.2%)
Low average 34 (20.1%) 90 (36.5%)
Low 5 (2.9%) 6 (2.4%)
Kt/V urea (per week) 2.360.5 2.560.7 NS
Cardiovascular disease, n (%) 94 (55.6%) 51 (20.7%) ,0.001
Ejection fraction (%) 52.8617.5 61.469.8 0.03
History of smoking, n (%) 41 (24.2%) 87 (35.3%) 0.02
Amount of smoking (pack-years)35.1624.0 24.1618.2 0.03
Systolic blood pressure (mmHg)139.3621.8 139.8619.8 NS
BMI (kg/m2) 22.663.0 22.663.1 NS
Hemoglobin (g/dL) 9.261.4 9.261.6 NS
Total cholesterol (mg/dL) 147.7643.5 158.8643.4 0.02
Ca6 P product (mg2/dL2) 41.6612.7 43.9612.6 NS
iPTH (pg/mL) 138.46123.8 213.56176.0 ,0.001
Albumin (g/dL) 3.460.5 3.560.6 0.008
Log hs-CRP (mg/L) 0.160.6 –0.260.9 ,0.001
Lipid-lowering therapy, n (%) 80 (47.3%) 65 (26.4%) ,0.001
Antihypertensive drugs, n (%)
RAS blockers 128 (75.7%) 189 (76.8%) NS
Beta-blockers 105 (62.1%) 111 (45.1%) 0.03
Calcium channel blockers 107 (63.3%) 150 (60.9%) NS
Phosphate binders, n (%) NS
Calcium-based 88 (52.0%) 126 (51.2%)
Non calcium-based 13 (7.6%) 19 (7.7%)
Data are expressed as mean 6 standard deviation or number of patients
(percent).
Kt/V, fractional urea clearance; BMI, body mass index; Ca, calcium; P, phosphate;
iPTH, intact parathyroid hormone; hs-CRP, high sensitivity C-reative protein;
RAS, Renin-angiotensin system; NS, not significant.
doi:10.1371/journal.pone.0048793.t001
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Presence of AoAC at Baseline as an Independent Risk
Factor for All-cause and Cardiovascular Mortality
During a mean follow-up duration of 34.2620.4 months, 90
patients (21.7%) died. Among them, 39 patients (43.3%) died from
cardiovascular causes. Both the all-cause and cardiovascular
mortality-free survival rates were significantly lower in patients
with baseline AoAC (log-rank test, P,0.001) (Figure 1). Univariate
Cox proportional hazard analysis showed older age, presence of
diabetes and previous cardiovascular disease, usage of lipid-
lowering medication, increased Ca 6 P products and hs-CRP
levels, decreased albumin concetrations, and presence of AoAC at
baseline were significant risk factors for all-cause and cardiovas-
cular mortality. In multivariate Cox analysis, the presence of
baseline AoAC was revealed as a significant independent predictor
of all-cause [Hazard ratio (HR): 2.181, 95% CI: 1.336–3.561,
P=0.002] and cardiovascular mortality (HR: 3.582, 95% CI:
1.577–8.132, P=0.002). Previous history of cardiovascular disease
and higher hs-CRP levels were also found to be independent risk
factors for all-cause and cardiovascular mortality. In contrast,
older age was independently associated only with all-cause
mortality (Table 2).
Progression of AoAC: Subgroup Analysis According to
the Presence of Baseline AoAC
Follow-up chest X-rays at 12 months after PD start were
available in 363 patients. Among them, 140 patients (38.5%) had
AoAC at baseline and 223 patients (61.5%) did not. The
progression of AoAC was significantly more observed in patients
with AoAC at baseline (P,0.001). Among 140 patients with
AoAC at baseline, 90 patients (64.2%) experienced AoAC
progression, whereas AoAC progressed in only 12 (5.3%) out of
223 patients without baseline AoAC. Two hundred eleven patients
with AoACS of zero at baseline remained free of AoAC during the
12-month follow-up.
Pearson’s correlation analysis revealed that changes in AoACS
were significantly associated with baseline AoACS (r=0.389,
P,0.001), age (r=0.301, P,0.001), and time-averaged hs-CRP
(r=0.167, P=0.001) and calcium concentrations (r=0.124,
P=0.02). In multivariate binary logistic regression analysis,
baseline AoACS (OR: 1.803, 95% CI: 1.383–2.349, P,0.001),
age (OR: 1.058, 95% CI: 1.016–1.101, P=0.006), and hs-CRP
levels (OR: 1.904, 95% CI: 1.180–3.070, P=0.008) were found to
be independent risk factors associated with AoAC progression.
Since the baseline AoACS was significantly correlated with AoAC
progression, subgroup analysis was performed to clarify the
independent predictor for AoAC progression in patients with
and without baseline AoAC. In patients with AoAC at baseline,
there was a significant correlation between hs-CRP concentrations
and the changes in AoACS (r=0.248, P=0.02), while changes in
AoACS were significantly associated with age (r=0.124, P=0.04)
and hs-CRP levels (r = 0.126, P=0.036) in patents without
baseline AoAC. However, the changes in Ca 6 P products and
Figure 1. Kaplan-Meier analysis of (A) all-cause and (B) cardiovascular mortality in 415 patients. Patients with baseline aortic arch
calcification (AoAC) showed significantly higher all-cause and cardiovascular mortality than those without (both log-rank test, P,0.001).
doi:10.1371/journal.pone.0048793.g001
Table 2. Multivariate Cox’s proportional hazard models of
baseline aortic arch calcification (AoAC) all-cause and
cardiovascular mortality.
All- cause mortality Cardiovascular mortality
HR 95% CI P HR 95% CI P
Age (years) 1.048 1.022–1.074 ,0.001 1.028 0.988–1.069 NS
Male gender 1.136 0.660–1.954 NS 0.554 0.254–1.206 NS
Diabetes mellitus 1.071 0.679–1.690 NS 0.772 0.389–1.532 NS
Cardiovascular
disease
2.000 1.143–3.500 0.015 3.807 1.441–10.054 0.007
History of smoking0.928 0.520–1.657 NS 0.522 0.226–1.209 NS
Lipid-lowering
therapy
1.027 0.629–1.676 NS 1.453 0.688–3.071 NS
Ca6P (mg2/dL2) 0.989 0.970–1.007 NS 1.002 0.972–1.032 NS
Albumin (g/dL) 0.763 0.520–1.118 NS 0.707 0.389–1.285 NS
Log hs-CRP (mg/L)1.725 1.257–2.367 ,0.001 1.769 1.044–2.996 0.034
Baseline AoAC 2.181 1.336–3.561 0.002 3.582 1.577–8.132 0.002
Ca, calcium; P, phosphate; hs-CRP, high sensitivity C-reative protein; HR, hazard
ratio; CI, confidence interval; NS, not significant.
doi:10.1371/journal.pone.0048793.t002
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iPTH concentrations did not correlate with changes in AoACS in
both subgroups.
Similar findings were observed in binary logistic regression
analysis. In patients with AoAC at baseline, univariate analysis
reavealed that diabetes mellitus, previous cardiovascular disease,
lipid-lowering therapy, hs-CRP levels, and baseline AoACS were
significantly associated with AoAC progression. In multivariate
binary logistic regression models, baseline AoACS (OR: 1.234,
95% CI: 1.104–5.197, P=0.027) and hs-CRP levels (OR: 2.238,
95% CI: 1.051–4.767, P=0.037) were independent predictors of
AoAC progression after adjustment for confounders. On the other
hand, in patients without baseline AoAC, age, previous cardio-
vascular disease, the use of lipid-lowering drugs, and hs-CRP levels
were significant predictors of AoAC progression in univariate
analysis. Multivariate binary logistic regression models demon-
strated that age (OR: 1.063, 95% CI: 1.014–1.113, P=0.002) and
hs-CRP concentrations (OR: 1.294, 95% CI: 1.019–4.581,
P=0.035) were significant risk factors for AoAC progression.
However, peritoneal membrane transport characteristics, weekly
Kt/V urea, Ca x P products, iPTH concentrations, and the use of
phosphate binders were not significantly associated with AoAC
progression in both subgroups.
Progression of AoAC as an Independent Risk Factor for
Mortality
In patients with AoAC at baseline, all-cause and cardiovascular
death rates were significantly higher in the AoAC progression
group (19.8 vs. 8.6 and 11.0 vs. 3.8 per 100 Person-Years,
respectively, P,0.001). Results were similar even when the
analysis was performed using only patients without baseline
AoAC. In the progression groups, all-cause and cardiovascular
death rates were 11.1 and 4.4 per 100 Person-Years, respectively.
These rates were significantly higher than those of the non-
progression group (2.2 and 0.6 per 100 Person-Years, respectively,
P,0.001) (Table 3).
Kaplan-Meier analysis and Cox proportional hazard models
(Figure 2 and Table 4) were used to determine the prognostic
value of AoAC progression on mortality. In patients with baseline
AoAC, patients with AoAC progression had significantly lower all-
cause and cardiovascular mortality-free survival rates compared to
patients without progression (log-rank test, P=0.002 and 0.016,
respectively). In addition, AoAC progression along with previous
history of cardiovascular disease and hs-CRP levels was found to
be significantly associated with all-cause and cardiovascular
mortality in univariate Cox analysis. However, multivariate Cox
proportional hazard analysis revealed that AoAC progression was
an independent predictor of all-cause (HR: 2.625, 95% CI: 1.15–
5.991, P=0.022) and cardiovascular mortality (HR: 4.008, 95%
CI: 1.079–14.890, P=0.038). Similarly, in the subgroup of
patients without baseline AoAC, Kaplan-Meier analysis showed
that patients with AoAC progression had significantly higher risks
for all-cause (P,0.001) and cardiovascular mortality (P=0.003).
Moreover, in univariate analysis, age, previous history of
cardiovascular disease, the use of lipid-lowering drugs, and hs-
CRP concentrations as well as AoAC progression were demon-
strated to be significant risk factors for all-cause and cardiovascular
mortality. However, subsequent multivariate Cox proportional
hazard models found that AoAC progression was a significant
independent predictor of all-cause mortality (HR: 3.408, 95% CI:
1.028–11.300, P=0.045), but not of cardiovascular mortality (HR:
5.935, 95% CI: 0.912–36.995, P=0.057).
Discussion
Vascular calcification is common in ESRD patients and closely
linked with cardiovascular disease, the leading cause of death in
this population [1,5,8,9,10,11]. In this study, we demonstrate that
AoAC presence at the initiation of dialysis is a significant predictor
for all-cause and cardiovascular mortality in a relatively large
number of incident PD patients. In addition, AoAC progression
was found to be associated with patient outcome, irrespective of
the presence of AoAC at baseline.
Accumulating evidence has shown that vascular calcification is
highly prevalent in ESRD patients [6,7] and that it is associated
with increased vascular stiffness and decreased vascular compli-
Table 3. All-cause and cardiovascular death rates according to the presence of aortic arch calcification (AoAC) at baseline and
progression of AoAC.
No. of events Follow-up, Event rate per
/No. of patients No. of Person-Years 100 Person-Years
All-cause death
Baseline AoAC present group (n= 140)
Progression (+) 27/90 136.3 19.8
Progression (2) 9/50 104.6 8.6
Baseline AoAC absent group (n=223)
Progression (+) 5/12 45.0 11.1
Progression (2) 19/211 863.3 2.2
Cardiovascular death
Baseline AoAC present group (n= 140)
Progression (+) 15/90 136.3 11.0
Progression (2) 4/50 105.2 3.8
Baseline AoAC absent group (n=223)
Progression (+) 2/12 45.4 4.4
Progression (2) 6/211 998.3 0.6
doi:10.1371/journal.pone.0048793.t003
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ance, resulting in left ventricular (LV) hypertrophy and LV
diastolic dysfunction [21,22]. Furthermore, arterial stiffness leads
to a decrease in diastolic blood pressure, which can compromise
coronary perfusion to increase LV mass, irrespective of preexisting
coronary artery disease [23,24]. Based on these findings, some
investigators have suggested that vascular calcification may
contribute in part to significantly high cardiovascular mortality
in ESRD. In accordance with most previous studies, this study
showed AoAC presence at the start of PD was a significant
independent predictor of all-cause and cardiovascular mortality in
incident PD patients [3,11,18].
The prevalence of AoAC at baseline was 40.7% in this study,
which was much lower than that of most previous studies from
Western countries [2,3,13,14,25]. In the study by Ogawa et al
[11], however, only 50.6% of 401 prevalent HD patients with
dialysis duration of more than 8 years had AoAC. A study on 184
Korean incident dialysis patients also showed that AoAC was
present in 41.3% before initial dialysis, which is comparable with
the results of our study [26]. Taken together, the prevalence of
vascular calcification in ESRD patients seems to be highly variable
depending on not only the screening technique but also the studied
population, such as ethnicity and BMI. Meanwhile, the proportion
of smokers was significantly lower in patients with AoAC at
baseline in this study. Most previous studies demonstrated that
smoking was a significant risk factor for AoAC and that a dose-
response relationship was observed between the amount of
smoking and AoAC [27,28]. Moreover, several studies revealed
that smoking cessation decreased the risk of AoAC in some light
ex-smokers [28,29]. Considering these findings, we surmised that
that the amount of smoking might be a possible explanation for the
discrepancy in the association between smoking status and the risk
of AoAC, and therefore re-evaluated the data of cigarette
consumption and calculated pack-years of smoking in smokers.
In result, compared to the baseline AoAC absent group, the mean
amount of smoking was significantly higher in patients with
baseline AoAC despite lower proportion of smokers. Furthermore,
when smokers were dichotomized by the median value of the
amount of smoking, the proportion of patients with AoAC at
baseline was significantly higher in heavy smokers compared to
light smoker group (26.2% vs. 13.4%, P=0.04). Based on these
findings, it was presumed that not only the smoking status but also
the amount of smoking could affect the risk of AoAC. However,
Figure 2. Kaplan-Meier analysis of aortic arch calcification (AoAC) progression for all-cause and cardiovascular mortality according
to baseline AoAC subgroups. In baseline AoAC present group, patients with AoAC progression showed significantly higher all-cause (A) and
cardiovascular (B) mortality (log-rank test, P= 0.002 and P=0.016, respectively). Patients with AoAC progression in baseline AoAC absent group also
showed significantly higher all-cause (C) and cardiovascular (D) mortality (P,0.001 and P= 0.003, respectively).
doi:10.1371/journal.pone.0048793.g002
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due to limited information about detailed smoking status (ex- or
current smoker), the relationship of the smoking status and the
amount of smoking with AoAC could not be thoroughly clarified
in this study.
Compared to previous studies on the association of various
parameters with vascular calcification and the clinical conse-
quences of vascular calcification, the risk factors for the
progression of vascular calcification are largely unexplored in
dialysis patients. In addition, impacts of the vascular calcification
progression on these patients’ outcome have not been elucidated.
A previous study by Sigrist et al [14] investigated the independent
factors associated with the progression of vascular calcification and
the influence of it on mortality over 24 months in 134 patients with
stage 4 and 5 CKD. It found that progressive calcification was
associated with age, male gender, and serum alkaline phosphatase
levels. Similarly, the NECOSAD study showed that age,
hypercalcemia, hyperparathyroidism, and the interval between
the first and last assessed AoACS were significantly linked with an
increase in calcification score over time [3]. Kim et al [26] also
found that age, dialysis duration, and the presence of AoAC were
related to AoAC progression. However, in those studies, about
two-thirds of patients were HD patients. In addition, changes in
calcification score were significantly higher in HD patients than in
PD patients. Moreover, the interval between the first and last
measurement of AoACS was inconsistent in the NECOSAD study
[3]. In this study, only incident PD patients were included and the
interval between the first and follow-up AoACS assessment was 12
months in all patients. Therefore, the results of the aforementioned
studies may not be applicable to ours. Even though age was
significantly associated with AoAC progression in our subjects,
when analysis was preformed separately according to the baseline
AoAC presence, the association of age and AoACS with
progression remained meaningful only in patients without baseline
AoAC. Considering that age was significantly higher in patients
with baseline AoAC than in patients without, we surmised that the
effect of age on AoAC progression might be lessened in elderly
incident PD patients who already had AoAC.
In the present study, AoAC progression was an independent
predictor of unfavorable outcome in incident PD patients, which is
in agreement with the results of most previous studies [3,11,18].
However, the mechanism by which AoAC progression influences
mortality in ESRD patients has not been fully understood. We
suppose that a different type of vascular calcification can be one of
the possible mechanisms. London et al [9] examined the impact of
intimal and medial calcification on the prognosis in prevalent HD
patients and found that arterial medial calcification (AMC) was a
much stronger predictor of mortality than arterial intimal
calcification in these patients. On the other hand, it is well known
that chronic inflammation, malnutrition, and atherosclerosis are
closely linked with each other in ESRD patients [30]. Further-
more, the current study demonstrated that AoAC progression was
observed even in patients without baseline AoAC and that AoAC
progression was significantly associated with elevated hs-CRP
levels in both baseline AoAC present and absent groups. Based on
these findings, we surmised that AoAC progression was associated
with AMC progression specific to dialysis therapy. A previous
study also revealed that the reason of higher mortality in patients
with AMC was attributed to increased arterial stiffness [31].
Increased arterial stiffness may cause vessel wall damage,
atherosclerosis, and high pulse pressure, which were independent
prognostic factors in ESRD [9,31].
Mounting evidence has shown a close interrelationship among
malnutrition, inflammation, and atherosclerosis [30]. In addition,
atherosclerosis is closely associated with vascular and cardiac
valvular calcification [32,33]. Based on these findings, chronic
inflammation has also been suggested to be implicated in the
pathogenesis and progression of vascular calcification in dialysis
patients and we also found that hs-CRP concentrations were
significantly associated with the changes in AoACS in incident PD
patients, irrespective of the presence of baseline AoAC. However,
the association of hs-CRP levels with the progression of vascular
calcification was not consistent. Previous studies demonstrated that
CRP was independently associated with the progression of
coronary artery calcification over a 24-month period in 40
prevalent HD patients and was identified as an independent risk
factor for the progression of abdominal aortic calcification over 3
years in 71 prevalent HD patients [34,35]. In contrast, other
studies failed to identify association between CRP levels and the
Table 4. Cox’s proportional hazard models of aortic arch calcification (AoAC) progression for all-cause and cardiovascular
mortality.
Unadjusted Adjusted
HR (95% CI) P HR (95% CI) P
Baseline AoAC present group (n=140)
All-cause mortality
AoAC progression 2.679 (1.255–5.717) 0.011 a2.625 (1.15–5.991) 0.022
Cardiovascular mortality
AoAC progression 3.506 (1.16–10.598) 0.026 a4.008 (1.079–14.890) 0.038
Baseline AoAC absent group (n=223)
All-cause mortality
AoAC progression 5.017 (1.853–13.587) 0.002 b3.408 (1.028–11.300) 0.045
Cardiovascular mortality
AoAC progression 7.026 (1.408–35.053) 0.017 b5.935 (0.912–36.995) NS
aAdjusted: adjusted for age, sex, presence of diabetes mellitus, previous cardiovascular disease, log high sensitivity C-reative protein, and albumin levels.
bAdjusted: adjusted for age, sex, presence of diabetes mellitus, previous cardiovascular disease, lipid-lowering therapy, log high sensitivity C-reactive protein, and
albumin levels.
HR, hazard ratio; CI, confidence interval; NS, not significant.
doi:10.1371/journal.pone.0048793.t004
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progression of vascular calcification in HD and/or PD patients
[3,36]. We surmised that failure to find this association was due to
a small number of patients, combined analysis of patients with
diverse dialysis modalities, and missing values. Since other
circulating markers of inflammation and various calcification
activators and inhibitors (such as bone morphogenetic proteins,
matrix GIa-protein, fetuin-A, and osteoprotegerin) were not
measured in this study [32,37,38,39], our results that hs-CRP is
the only non-traditional predictor of AoAC progression should be
interpreted with caution.
Conclusions
The present study shows that the presence of AoAC assessed by
chest X-ray at the start of dialysis and the progression of AoAC
during the first 12 months of dialysis were significant independent
risk factors for mortality in incident PD patients. Taken together,
regular follow-up by chest X-ray could be a simple and useful tool
to stratify mortality risk in these patients. In addition, efforts to
prevent development of vascular calcification and to attenuate
progression of vascular calcification are needed to improve these
patients’ outcomes.
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